NCI will immediately start the process of streamlining IND-exempt trials in order to make them faster, simpler, more flexible, less expensive, and easier to integrate with clinical practice, James Doroshow, NCI deputy director for clinical and translational research and director of the Division of Cancer Treatment and Diagnosis, said to The Cancer Letter. On Nov....
![](https://cdn.cancerletter.com/media/2022/11/11142406/Doroshow-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2022/11/11142406/Doroshow-4x3-1.jpg)